Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study

Molidustat, an orally administered hypoxia‐inducible factor prolyl‐hydroxylase inhibitor, is under development for the treatment of anemia of CKD. This 24‐week, phase 3, single‐arm, multicenter study evaluated the efficacy and safety of molidustat in Japanese patients with renal anemia who were undergoing hemodialysis and who were not receiving an erythropoiesis‐stimulating agent. Twenty‐five patients received molidustat at a starting dose of 75...